title: Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial.
abstract: BACKGROUND
  Patients with metastatic breast cancer (MBC) are frequently exposed to high cumulative doses of anthracyclines and are at risk of resistance and cardiotoxicity. This phase II trial evaluated the efficacy and toxicity of docetaxel plus cisplatin, as salvage chemotherapy in patients with MBC resistant to prior anthracyclines.
  
  
  METHODS
  Patients with MBC that had progressed after at least one prior chemotherapy regimen containing anthracyclines received docetaxel 75 mg/m2 followed by cisplatin 60 mg/m2 every 3 weeks for a maximum of 6 cycles or until disease progression.
  
  
  RESULTS
  Between Jan 2000 and May 2002, 24 patients with tumors primary resistant and 15 with secondary resistant disease were accrued. All 39 patients were evaluable for safety and 36 for efficacy. The objective response rate was 31% (95% CI, 16-45%) with 3 complete responses. The median time to disease progression was 7 months, and the median overall survival was 23 months (median follow-up of 41 months). Neutropenia was the most frequently observed severe hematologic toxicity (39% of patients), whereas asthenia and nausea were the most common non-hematologic toxicities. No treatment-related death was observed.
  
  
  CONCLUSIONS
  In conclusion, we found docetaxel plus cisplatin to be an active and safe chemotherapy regimen for patients with MBC resistant to anthracyclines.
authors.affiliation: Division of Hematology and Oncology, Internal Medicine, Gachon Medical School Gil Medical Center, Incheon 405-760, Korea. hematoma@ghil.com
authors.forename: Se Hoon
authors.initials: SH
authors.lastname: Park
authors.forename: Eun Kyung
authors.initials: EK
authors.lastname: Cho
authors.forename: Soo-Mee
authors.initials: SM
authors.lastname: Bang
authors.forename: Dong Bok
authors.initials: DB
authors.lastname: Shin
authors.forename: Jae Hoon
authors.initials: JH
authors.lastname: Lee
authors.forename: Young Don
authors.initials: YD
authors.lastname: Lee
mesh_terms: D000328:Adult; D018943:Anthracyclines / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D001932:Brain Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008875:Middle Aged; D016879:Salvage Therapy; D012983:Soft Tissue Neoplasms / Q000401:mortality / Q000556:secondary*; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D018943:Anthracyclines; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin
references.citation: Biometrics. 1982 Mar;38(1):143-51
references.pmid: 7082756
references.citation: Breast Cancer Res Treat. 2003;79 Suppl 1:S11-8
references.pmid: 12868801
references.citation: N Engl J Med. 1994 May 5;330(18):1253-9
references.pmid: 8080512
references.citation: Anticancer Drugs. 1995 Jun;6(3):339-55, 363-8
references.pmid: 7670132
references.citation: J Clin Oncol. 1995 Dec;13(12):2879-85
references.pmid: 8523050
references.citation: J Clin Oncol. 1995 Dec;13(12):2886-94
references.pmid: 8523051
references.citation: J Clin Oncol. 1996 Apr;14(4):1185-91
references.pmid: 8648373
references.citation: J Clin Oncol. 1997 Mar;15(3):1071-9
references.pmid: 9060547
references.citation: J Clin Oncol. 1998 Oct;16(10):3362-8
references.pmid: 9779713
references.citation: Ann Oncol. 1999 Jan;10(1):119-22
references.pmid: 10076732
references.citation: Semin Oncol. 1999 Feb;26(1 Suppl 3):5-9
references.pmid: 10203264
references.citation: Anticancer Res. 1999 Jan-Feb;19(1A):291-9
references.pmid: 10226557
references.citation: J Clin Oncol. 1999 May;17(5):1413-24
references.pmid: 10334526
references.citation: Semin Oncol. 1999 Jun;26(3 Suppl 11):13-8
references.pmid: 10458205
references.citation: Semin Oncol. 2001 Feb;28(1 Suppl 3):28-37
references.pmid: 11301372
references.citation: J Clin Oncol. 1999 Jul;17(7):2069-80
references.pmid: 10561260
references.citation: J Clin Oncol. 1999 Sep;17(9):2971-94
references.pmid: 10561376
references.citation: Eur J Cancer. 1999 Aug;35(8):1194-201
references.pmid: 10615229
references.citation: Cancer. 2000 Jan 1;88(1):124-31
references.pmid: 10618614
references.citation: Ann Oncol. 1999 Nov;10(11):1385-8
references.pmid: 10631471
references.citation: Ann Oncol. 1999 Dec;10(12):1457-60
references.pmid: 10643536
references.citation: Ann Oncol. 2000 Mar;11(3):301-6
references.pmid: 10811496
references.citation: J Clin Oncol. 2001 Jan 15;19(2):336-42
references.pmid: 11208824
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: Jpn J Cancer Res. 2002 May;93(5):574-81
references.pmid: 12036454
references.citation: Oncol Rep. 2002 Nov-Dec;9(6):1345-9
references.pmid: 12375046
references.citation: Oncologist. 2002;7 Suppl 6:4-12
references.pmid: 12454314
references.citation: Oncology. 2003;64(3):207-12
references.pmid: 12697959
references.citation: Semin Oncol. 1989 Aug;16(4 Suppl 6):110-5
references.pmid: 2669132